Skip to content
10-Q

Quarterly Report

SILK ROAD MEDICAL, INC.

0001397702-24-000034

← back to feed
Filed
May 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · Apr 30, 2024 39.44M sh
Shares Diluted Q1 2024 · Mar 31, 2024 39.26M sh
Shares Diluted Q1 2024 · Mar 31, 2023 38.53M sh
Capex Q1 2024 · Mar 31, 2024 $388K
Capex Q1 2024 · Mar 31, 2023 $287K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$15.32M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$12.15M
Long Term Debt Q1 2024 · Mar 31, 2024 $75.89M
Long Term Debt Q1 2024 · Dec 31, 2023 $75.63M
Short Term Investments Q1 2024 · Mar 31, 2024 $151.83M
Short Term Investments Q1 2024 · Dec 31, 2023 $161.26M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $22.63M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $20.21M
Stockholders Equity Q1 2024 · Mar 31, 2024 $147.29M
Stockholders Equity Q1 2024 · Dec 31, 2023 $151.15M
Current Liabilities Q1 2024 · Mar 31, 2024 $21.34M
Current Liabilities Q1 2024 · Dec 31, 2023 $30.28M
Total Liabilities Q1 2024 · Mar 31, 2024 $105.03M
Total Liabilities Q1 2024 · Dec 31, 2023 $114.16M
Current Assets Q1 2024 · Mar 31, 2024 $235.69M
Current Assets Q1 2024 · Dec 31, 2023 $240.84M
Total Assets Q1 2024 · Mar 31, 2024 $252.31M
Total Assets Q1 2024 · Dec 31, 2023 $265.31M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.36
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.43
Eps Basic Q1 2024 · Mar 31, 2024 −$0.36
Eps Basic Q1 2024 · Mar 31, 2023 −$0.43
Sga Expense Q1 2024 · Mar 31, 2024 $40.78M
Sga Expense Q1 2024 · Mar 31, 2023 $34.08M
Rd Expense Q1 2024 · Mar 31, 2024 $10.66M
Rd Expense Q1 2024 · Mar 31, 2023 $10.43M
Net Income Q1 2024 · Mar 31, 2024 −$14.14M
Net Income Q1 2024 · Mar 31, 2023 −$16.46M
Operating Income Q1 2024 · Mar 31, 2024 −$14.93M
Operating Income Q1 2024 · Mar 31, 2023 −$16.91M
Gross Profit Q1 2024 · Mar 31, 2024 $36.5M
Gross Profit Q1 2024 · Mar 31, 2023 $27.61M
Cost Of Revenue Q1 2024 · Mar 31, 2024 $11.98M
Cost Of Revenue Q1 2024 · Mar 31, 2023 $12.53M
Revenue Q1 2024 · Mar 31, 2024 $48.48M
Revenue Q1 2024 · Mar 31, 2023 $40.13M